Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics.
Lead Product(s): Epinephrine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Adrenaline Aguettant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Juno Pharmaceuticals Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 24, 2022